Aripiprazole Tablet
Product Images NDC 72789-462

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 72789-462). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (72789462)

The packaging label for Aripiprazole USP 5 mg tablets by PD-Rx Pharmaceuticals, Inc. The label features the NDC 72789-462-14, indicating a package of 14 tablets. It includes dosage warnings, instructions to call a doctor for side effects, and details such as lot number L24D97 and expiration date 01/2026. The label is printed in black, white, and purple with the PD-Rx logo and contact information.*

FDA Label Image

Figure1 (Figure1)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold changes in Aripiprazole's AUC and Cmax with 90% confidence intervals. It compares the impact of various interacting drugs including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam) on Aripiprazole exposure relative to a reference without interacting drugs.*

FDA Label Image

Figure2 (Figure2)

A horizontal bar chart titled 'Effect of Other Drugs on Aripiprazole' shows the fold change and 90% confidence interval (CI) for the pharmacokinetic parameters AUC and Cmax. Drugs are categorized as CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and others, with corresponding fold changes relative to a reference without interacting drug.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for various drugs and enzymes relative to reference without interacting drug. The x-axis represents the change relative to reference (0.5 to 3.0). The y-axis lists CYP2D6, CYP2C9/CYP2C19, warfarin, omeprazole, UGT1A4, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. Data points with error bars indicate pharmacokinetic parameters such as AUC and Cmax changes.*

FDA Label Image

Figure4 (Figure4)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' illustrating changes in AUC and Cmax for aripiprazole across special populations, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis represents change relative to reference values.*

FDA Label Image

Figure5 (Figure5)

A pharmacokinetic chart titled "Dehydro-Aripiprazole Fold Change and 90% CI" showing fold changes in AUC and Cmax for various factors including CYP2D6 metabolism status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis represents change relative to reference, with data points and confidence intervals for each factor comparison.*

FDA Label Image

Figure6 (Figure6)

Kaplan-Meier curve chart showing the proportion of subjects with relapse over 182 days from randomization. It compares two groups: Aripiprazole and Placebo, with the proportion of relapse on the vertical axis and days from randomization on the horizontal axis. The chart includes the number of subjects at risk over time for both groups.*

FDA Label Image

Figure7 (Figure7)

A Kaplan-Meier curve showing the proportion of subjects with relapse over time (days from randomization) comparing Aripiprazole 5 mg oral tablets to placebo. The graph shows two lines representing Aripiprazole and placebo groups, with numbers of subjects at risk listed below.*

FDA Label Image

Figure8 (Figure8)

A Kaplan-Meier curve chart comparing the proportion of subjects with relapses over 364 days from randomization between Aripiprazole and Placebo groups. The graph plots days elapsed on the X-axis and proportion with relapse on the Y-axis, showing lower relapse proportion for Aripiprazole (solid line) than Placebo (dashed line). Subject counts at risk per time point are tabulated below the graph.*

FDA Label Image

Figure9 (Figure9)

A line graph depicting the change in YGTSS total TIC score from baseline over 8 weeks of treatment. It compares three groups: Abilify Low dose, Abilify High dose, and Placebo, showing least-squares mean changes in scores on the y-axis and weeks of treatment on the x-axis.*

FDA Label Image

Structure-1 (Structure 1)

Chemical structure of Aripiprazole, the active ingredient in the referenced product, showing its molecular configuration with aromatic rings, chlorine atoms, and heterocycles.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.